Fortis Healthcare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+17.3%+12.9%+9.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+31.3%+25.3%+15.1%
+36.0%+30.0%+17.8%
+31.5%+25.4%+1.9%
+34.5%+29.4%+1.7%
+16.6%+3.0%+6.9%
+10.9%+7.2%+5.6%
+12.5%+29.4%+33.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

FORTIS₹754.90

Fortis Healthcare Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHMEDANTAAUROPHARMALUPINALKEMLAURUSLABSMANKINDMcap ₹56,992 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+9.5+12.9+17.3—
EBITDA Growth—+15.1+25.3+31.3—
EBIT Growth—+17.8+30.0+36.0—
Net Income Growth—+1.9+25.4+31.5—
EPS Growth—+1.7+29.4+34.5—
Total Assets Growth—+6.9+3.0+16.6—
Total Equity Growth—+5.6+7.2+10.9—
Cash from Operations Growth—+33.8+29.4+12.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.